In Vivo Optical Imaging of Beta-Emitting Radionuclides using Cerenkov Radiation

使用切伦科夫辐射对 β 发射放射性核素进行体内光学成像

• 批准号: 7770647
• 负责人: Simon R Cherry
• 金额: $ 16.64万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2011-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7770647
• 关键词: 3-Dimensional; 90Y; Algorithms; Animals; Back; Bioluminescence; Cells; Charge; Data; Detection; Development; Devices; Diagnostic; Dose; Dyes; Firefly Luciferases; Fluorescence; Gamma Rays; Histocompatibility Testing; Ibritumomab Tiuxetan; Image; Knowledge; Light; Location; Luc Gene; Malignant Neoplasms; Measurement; Methodology; Methods; Modeling; Monitor; Mus; Optics; Penetration; Performance; Photons; Positron; Positron-Emission Tomography; Production; Quantum Dots; Radiation; Radioactive; Radioimmunotherapy; Radioisotopes; Radionuclide therapy; Radiopharmaceuticals; Refractive Indices; Resolution; Series; Signal Transduction; Site; Source; Speed; Surface; System; Techniques; Testing; Therapeutic; Therapeutic Studies; Time; Tissues; Validation; Work; Y 90 Ibritumomab Tiuxetan; base; charge coupled device camera; clinical application; cost; fluorodeoxyglucose; imaging modality; improved; in vivo; iodine-131-tositumomab; luminescence; molecular imaging; nanoparticle; optical imaging; particle; pre-clinical; public health relevance; radiotracer; reconstruction; single photon emission computed tomography; tomography; tool; tositumomab; tumor

DESCRIPTION (provided by applicant): 2-emitting radionuclides used for diagnostic (positron emission tomography, PET) and therapeutic (radionuclide therapy in cancer) purposes are typically energetic enough to produce Cerenkov light subsequent to their radioactive decay in tissue. We demonstrate that the light levels produced by these 2- particles are sufficient for external detection of these radionuclides in a mouse using a sensitive charge- coupled device (CCD) camera, thus enabling the distribution of 2-emitting radionuclides to be imaged in vivo using widely available optical imaging systems. We propose to further characterize and optimize the use of Cerenkov light for in vivo small animal molecular imaging, especially for applications involving radionuclide therapies to treat cancer. We also will show how Cerenkov imaging can be used to image the distribution of PET radiotracers using an optical imaging system. Studies will focus on three radionuclides, 18F (a pure 2+ emitter), 90Y (a pure 2- emitter) and 131I (emits both 2--particles and gamma rays). Both 90Y and 131I are clinically used as therapeutic radionuclides. We also propose to develop 3-dimensional Cerenkov luminescence tomography, and show that this has a close relationship to standard bioluminescence tomography. The significance of this work is that for the first time, it allows the distribution of pure 2-emitting radionuclides such as 90Y to be imaged sensitively in vivo, and it also permits the imaging of positron-emitting radiotracers on simple, and widely available optical imaging systems. We think imaging of Cerenkov light will be a powerful new imaging methodology for preclinical molecular imaging and therapeutic studies, and may have certain clinical applications for monitoring therapies involving 2-emitting radionuclides where the target sites can be accessed endoscopically. PUBLIC HEALTH RELEVANCE: 2-emitting radionuclides used for diagnostic (positron emission tomography) and therapeutic (radionuclide therapy in cancer) purposes produce Cerenkov light subsequent to their radioactive decay in tissue. We demonstrate that the light levels are sufficient for external detection using a sensitive charge-coupled device (CCD) camera, thus enabling the distribution of these radionuclides to be imaged using widely available optical imaging systems. The significance of this discovery is that it allows the distribution of pure 2-emitting radionuclides, such as 90Y, to be imaged sensitively in vivo, and it also permits the imaging of positron-emitting radiotracers on simple optical imaging systems.

描述（由申请人提供）： 2-用于诊断（正电子发射断层摄影术，PET）和治疗（癌症中的放射性核素治疗）目的的发射放射性核素通常具有足够的能量，以在它们在组织中的放射性衰变之后产生切伦科夫光。我们证明，由这些2-粒子产生的光水平是足够的外部检测这些放射性核素在小鼠中使用敏感的电荷耦合器件（CCD）相机，从而使2-发射放射性核素的分布在体内成像使用广泛可用的光学成像系统。我们建议进一步表征和优化切伦科夫光用于体内小动物分子成像，特别是用于涉及放射性核素疗法治疗癌症的应用。我们还将展示如何切伦科夫成像可以用来使用光学成像系统的PET放射性示踪剂的分布图像。研究将侧重于三种放射性核素，18 F（纯2+发射体）、90 Y（纯2-发射体）和131 I（发射2-粒子和伽马射线）。90 Y和131 I在临床上都被用作治疗性放射性核素。我们还建议开发三维切伦科夫发光断层扫描，并表明，这有一个密切的关系，标准的生物发光断层扫描。这项工作的意义在于，它首次允许纯2-发射放射性核素如90 Y的分布在体内灵敏地成像，并且它还允许在简单且广泛可用的光学成像系统上对正电子发射放射性示踪剂进行成像。我们认为切伦科夫光成像将是一种强大的新的成像方法，用于临床前分子成像和治疗研究，并可能具有一定的临床应用，用于监测涉及2-发射放射性核素的治疗，其中靶点可以通过内窥镜进入。 公共卫生相关性： 2-用于诊断（正电子发射断层摄影术）和治疗（癌症中的放射性核素治疗）目的的发射放射性核素在它们在组织中的放射性衰变之后产生切伦科夫光。我们证明，光水平是足够的外部检测使用敏感的电荷耦合器件（CCD）相机，从而使这些放射性核素的分布使用广泛可用的光学成像系统成像。这一发现的重要性在于，它允许在体内灵敏地成像纯2-发射放射性核素（如90 Y）的分布，并且它还允许在简单的光学成像系统上成像正电子发射放射性示踪剂。